Ascendis Pharma A (ASND) Capital Expenditures (2014 - 2024)
Ascendis Pharma A (ASND) reported Capital Expenditures of -$512868.5 for Q3 2024, up 51.73% on a YoY basis from -$338017.5 in Q4 2023, and down 39.25% sequentially from -$368295.6 in Q2 2024.
Ascendis Pharma A (ASND) Capital Expenditures (2014 - 2024) Analysis & Trends
Ascendis Pharma A (ASND) has 11 years of Capital Expenditures data on file, last reported at -$512868.5 in Q3 2024.
- For the quarter ending Q3 2024, Capital Expenditures rose 51.73% year-over-year to -$512868.5; the trailing twelve-month figure through Sep 2024 stood at -$1.0 million (up 84.33% YoY), and the FY2023 full-year result was -$2.6 million, up 82.7% from the prior year.
- Capital Expenditures retreated to -$512868.5 in Q3 2024, from -$368295.6 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $48.7 million in Q4 2021 to a low of -$13.3 million in Q3 2021.
- A 5-year average of $1.7 million and a median of -$3.2 million in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 315.62% in 2020, while the deepest fall reached 1344.86% in 2020.
- Tracing ASND's Capital Expenditures over 5 years: stood at $42.3 million in 2020, then advanced by 15.31% to $48.7 million in 2021, then sank by 107.92% to -$3.9 million in 2022, then jumped by 101.76% to $67784.2 in 2023, then sank by 856.62% to -$512868.5 in 2024.
- Business Quant data shows ASND's Capital Expenditures at -$512868.5 in Q3 2024, -$368295.6 in Q2 2024, and -$216186.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Ascendis Pharma A | 15.31 Bn | 14.64 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -512,868.51 |
| Sep 30, 2024 | -512,868.51 |
| Jun 30, 2024 | -368,295.55 |
| Jun 30, 2024 | -368,295.55 |
| Mar 31, 2024 | -216,185.99 |
| Mar 31, 2024 | -216,185.99 |
| Dec 31, 2023 | 67,784.21 |
| Dec 31, 2023 | 67,784.21 |
| Sep 30, 2023 | -1.06 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | -483,482.43 |
| Jun 30, 2023 | -483,482.43 |
| Mar 31, 2023 | -1.16 Mn |
| Mar 31, 2023 | -1.16 Mn |
| Dec 31, 2022 | -3.86 Mn |
| Dec 31, 2022 | -3.86 Mn |
| Sep 30, 2022 | -3.19 Mn |
| Sep 30, 2022 | -3.19 Mn |
| Jun 30, 2022 | -3.98 Mn |
| Jun 30, 2022 | -3.98 Mn |